Xeltis raises €47.5m to advance vascular implant commercialisation
Xeltis’ vascular access graft, aXess, recently demonstrated strong efficacy in an EU pivotal trial in patients with end-stage renal disease.
02 December 2025
02 December 2025
Xeltis’ vascular access graft, aXess, recently demonstrated strong efficacy in an EU pivotal trial in patients with end-stage renal disease.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.